In the News

Learn about a new FDA-approved treatment for pancreatic cancer in which MSK experts played a leading role in opening a new world of treatment options.

Learn how a simple surgical procedure can dramatically reduce the risk of developing ovarian cancer.

Learn how blood tests called liquid biopsies may be used to find, diagnose, and treat cancer anywhere in the body.

Learn more about a new radiopharmaceutical treatment for prostate cancer approved by the FDA for more patients.

Zidesamtinib, a new drug that treats non-small cell lung cancer carrying a mutation called a ROS1 fusion, has been approved by the FDA.

Learn how MSK is helping people with lung cancer driven by ROS1 fusions, thanks to continual improvements in specific targeted therapies.

MSK researchers identified a protein called ZFP36L2 that acts as a critical "molecular switch" controlling how gut cells repair themselves after injury — a mechanism that colorectal cancer hijacks to spread to other organs. The findings could point toward new treatments that exploit cancer cells' dependence on this protein to stop metastasis or overcome treatment resistance.

MSK experts say blood tests are not the best way to detect colorectal cancer and instead recommend colonoscopy or a stool test for those who can’t have a colonoscopy.

New MSK research uncovers why some leukemia patients stop responding to promising new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; creates the first atomic-level images of a key phosphate transporter that could inform treatment of ovarian cancer and kidney disease; finds Medicare Advantage patients with cancer receive optimal treatment at lower cost; and studies how much tissue surgeons should remove for tumor-related epilepsy.

Selpercatinib has received full FDA approval for treating tumors anywhere in the body that harbor a genetic change called a RET fusion.